WWL70
CAS No. 947669-91-2
WWL70( —— )
Catalog No. M22473 CAS No. 947669-91-2
WWL70 is a selective alpha/beta hydrolase domain 6 inhibitors (IC50: 70 nM). WWL70 (10 μM, 1 h) treatment, 2-Arachidonoylglycerol is increased by 20% compared to untreated cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 82 | In Stock |
|
| 10MG | 126 | In Stock |
|
| 25MG | 248 | In Stock |
|
| 50MG | 423 | In Stock |
|
| 100MG | 599 | In Stock |
|
| 200MG | 834 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameWWL70
-
NoteResearch use only, not for human use.
-
Brief DescriptionWWL70 is a selective alpha/beta hydrolase domain 6 inhibitors (IC50: 70 nM). WWL70 (10 μM, 1 h) treatment, 2-Arachidonoylglycerol is increased by 20% compared to untreated cells.
-
DescriptionWWL70 is a selective alpha/beta hydrolase domain 6 inhibitors (IC50: 70 nM). WWL70 (10 μM, 1 h) treatment, 2-Arachidonoylglycerol is increased by 20% compared to untreated cells. WWL70 (either 1 or 10 μM) completely blocks the lipopolysaccharide (LPS)-induced increase of PGE2. The enhanced mRNA expression of mPGES-1 and mPGES-2 by LPS is also reduced by WWL70. The IC50 of WWL70 to inhibit the PGE2 biosynthesis is about 100 nM.WWL70 treatment completely restores the ability of TBI mice to continuously alternate arms during Y maze exploration (69.67±4.98 %). WWL70 treatment improves motor coordination of traumatic brain injury mice in a concentration-dependent manner. The latency to fall in animals treated with WWL70 (5 mg/kg) increases from 74.92±4.8 to 99.57±5.21 on day 3 (p<0.01) and from 87.32±4.42 to 100.14±3.56 on day 7 (p<0.05) post-injury when compare with the vehicle-TBI groups. WWL70 (10 mg/kg) treatment improves motor coordination starting on day 1 post-injury.
-
In VitroAt 1 h after WWL70 (10 μM) treatment, 2-Arachidonoylglycerol (2-AG) is increased by 20% compare to untreated cells. At either 1 or 10 μM, WWL70 completely blocks the lipopolysaccharide (LPS)-induced increase of PGE2. The enhanced mRNA expression of mPGES-1 and mPGES-2 by LPS is also reduced by WWL70. The IC50 of WWL70 to inhibit the PGE2 biosynthesis is about 100 nM.
-
In VivoAlthough post-treatment with WWL70 at 5?mg/kg does not have any effect, treatment with WWL70 at 10?mg/kg improves the performance significantly. WWL70 treatment improves motor coordination of traumatic brain injury (TBI) mice in a concentration dependent manner. The latency to fall in animals treated with WWL70 at 5?mg/kg increases from 74.92±4.8 to 99.57±5.21 on day 3 (p<0.01) and from 87.32±4.42 to 100.14±3.56 on day 7 (p<0.05) post-injury when compare with the vehicle-TBI groups. At 10?mg/kg, WWL70 treatment improves motor coordination starting on day 1 post-injury. WWL70 treatment completely restores the ability of TBI mice to continuously alternate arms during Y maze exploration (69.67±4.98 %).
-
Synonyms——
-
PathwayWnt/Notch/Hedgehog
-
TargetWnt/beta/catenin
-
RecptorABHD6
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number947669-91-2
-
Formula Weight437.49
-
Molecular FormulaC27H23N3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:17.33 mg/mL (39.61 mM; Need ultrasonic)
-
SMILESCN(Cc1cccc(c1)-c1ccncc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Li W, et al. A functional proteomic strategy to discover inhibitors for uncharacterized hydrolases. J Am Chem Soc. 2007 Aug 8;129(31):9594-5.
molnova catalog
related products
-
Nesuparib
Nesuparib (JPI-547/OCN-201) is a potent PARP inhibitor with inhibitory effects on PARP and TNKS1.
-
NRX-103095
NRX-103095 is a potent enhancer of the interaction of β-catenin with the homologous E3 ligase SCFβ-TrCP and enhances the affinity of pSer33/Ser37 β-catenin for β-TrCP with an EC50 of 163 nM.
-
PRI-724 B
PRI-724 is a second-generation, selective small molecule inhibitor of the β-catenin/CBP interaction.
Cart
sales@molnova.com